81176-41-2

Basic information

• Product Name: 6-EPI PRAVASTATIN, SODIUM SALT
• Synonyms: 6-EPI PRAVASTATIN, SODIUM SALT;6-epi Pravastatin, Sodium Salt Discontinued;Pravastatin Related Compound B (20 mg) (sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-[[(2S)-2-methylbutanoyl]oxy]1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate);6'-epi Pravastatin;Pravastatin EP IMpurity A;6-Epi Pravastatin SodiuM;Pravastatin Related CoMpound B;(βR,δR,1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-naphthaleneheptanoic acid monosodium salt
• CAS NO: 81176-41-2
• Molecular Formula: C₂₃H₃₅O₇*Na
• Molecular Weight: 446.513
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 81176-41-2.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Solubility: Methanol, Water
• CAS DataBase Reference: 6-EPI PRAVASTATIN, SODIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: 6-EPI PRAVASTATIN, SODIUM SALT(81176-41-2)
• EPA Substance Registry System: 6-EPI PRAVASTATIN, SODIUM SALT(81176-41-2)

Safety Data

• Hazardous Substances Data: 81176-41-2(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Powder

Uses

An analogue of Pravastatin, a competitive inhibitor of HMG-CoA reductase.

Upstream product

• 81093-37-0 pravastatin 
• 73573-88-3 mevastatin 
• 81093-40-5 3β-hydroxy ML-236B methylester 
• 81093-37-0 3β-hydroxy ML-236B 

Downstream Products

• 85956-22-5 pravastatin lactone 
• 136590-28-8 R-195 
• 81093-37-0 pravastatin 
• 85798-96-5 lactone form of C-6 epimer of pravastatin 

Relevant articles and documents

CRYSTALLINE FORM OF PRAVASTATINE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to a novel form of pravastatin, notably pravastatin sodium, and a method for the preparation of a novel form of pravastatin.

PURIFICATION OF PRAVASTATIN

The present invention provides a method for the purification of pravastatin or a pharmacologically acceptable salt thereof by treating an aqueous solution comprising pravastatin with a nitrogen-containing base having a pKa value of 12 or higher. Furthermore, the present invention provides a composition comprising pravastatin sodium and 6-epi-pravastatin the quantity of which is 0.2% or less by weight of the composition and 3-α-isopravastatin the quantity of which is 0.2% or less by weight of the composition.

PROCESS FOR THE PREPARATION OF 1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (BETA R,DELTA R,1S,2S,6S,8S,8AR)-1-NAPHTHALENEHEPTANOIC ACID, SODIUM SALT.

A process for the preparation of substantially pure 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (beta R,delta R,1S,2S,6S,8S,8aR)- 1-Naphthaleneheptanoic acid, sodium salt is disclosed.